4D Medicine, a Nottingham-based company known for its innovative biomaterial for 3D printed implants and surgical devices, has successfully secured £3.4m ($4.4m) in a Series A investment. This funding round, led by Oshen Holdings and supported by DSW Ventures, SFC Capital, Boundary Capital, and private investors, marks a significant milestone for the company.
This investment will allow 4D Medicine to advance its pre-clinical testing for its initial product range and pursue FDA clearance to enter the US market. The company’s groundbreaking resorbable biomaterial, 4Degra, has shown promising results in early testing. Unlike traditional biomaterials that could lead to pain and inflammation, 4Degra degrades gradually without releasing harmful by-products.
With the ability to be 3D printed and utilized in various forms, including soft and hard formulations, 4Degra opens up a range of possibilities in the medical device industry. Founded in 2020, 4D Medicine has now raised a total of £5m, with plans to seek additional funding in a Series B round next year.
Philip Smith, CEO of 4D Medicine, expressed gratitude to investors for their continued support and belief in the company’s potential. The recent investment will be instrumental in completing pre-clinical testing and preparing for market entry in the orthopaedic sector.
Didier Cowling, Partner at Oshen Holdings, emphasized the game-changing potential of 4Degra in the bioresorbable medical device market. Similarly, Doug Quinn, Partner at DSW Ventures, highlighted the unique opportunities that 4D’s biomaterial platform offers.
The legal aspects of this funding were expertly handled by a team from Addleshaw Goddard and Hill Dickinson, ensuring compliance with regulatory requirements. The involvement of experienced legal advisors reflects the strategic approach taken by 4D Medicine in securing this investment.
